Results 91 to 100 of about 63,834 (200)
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
HIV Medicine, Volume 26, Issue 6, Page 858-869, June 2025.Abstract Introduction
Black and Hispanic/Latine people are disproportionately affected by HIV‐1 and may have a greater risk of comorbidities than non‐Black and non‐Hispanic/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies.C. Martorell, M. Ramgopal, D. Hagins, O. Osiyemi, J. R. Arribas, M. Berhe, Y. Yazdanpanah, C. Orkin, L. Santiago, C. Rosero, N. Unger, H. Liu, R. Rogers, J. T. Hindman, A. Wurapa +14 morewiley +1 more sourceAssessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use
HIV Medicine, Volume 26, Issue 6, Page 870-878, June 2025.Abstract Introduction
Integrase strand transfer inhibitors (INSTIs) are the mainstay of treatment in adults and children living with HIV. Weight gain has been associated with INSTI use in adults; however, less data exist on its effects on younger patients.Kathleen J. Pincus, Nabila Faridi, Patrick Amadeus Ryscavage, Hyunuk Seung, Kristine A. Parbuoni, Matthew Grant, Neha Sheth Pandit +6 morewiley +1 more sourceExploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs
Acta Pharmaceutica Sinica B, 2020 In this report, a series of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives were designed to explore the hydrophobic channel of the non-nucleoside reverse transcriptase inhibitors binding pocket (NNIBP) by incorporating an aromatic ...Dongwei Kang, Da Feng, Tiziana Ginex, Jinmi Zou, Fenju Wei, Tong Zhao, Boshi Huang, Yanying Sun, Samuel Desta, Erik De Clercq, Christophe Pannecouque, Peng Zhan, Xinyong Liu +12 moredoaj Rethinking HIV treatment: How non‐integrase strand regimens may hold the key to better immune health
HIV Medicine, Volume 26, Issue 6, Page 879-887, June 2025.Abstract Purpose
HIV outcome changed drastically with antiretroviral (ARV) therapy, especially after the introduction of second‐generation integrase strand transfer inhibitors (INSTIs). Despite these advances, however, chronic immune activation and exhaustion, marked by programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) upregulation ...Bogusz Aksak‐Wąs, Karolina Skonieczna‐Żydecka, Miłosz Parczewski, Rafał Hrynkiewicz, Filip Lewandowski, Karol Serwin, Kaja Mielczak, Franciszek Lenkiewicz, Paulina Niedźwiedzka‐Rystwej +8 morewiley +1 more sourceLate diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study
HIV Medicine, Volume 26, Issue 6, Page 888-898, June 2025.Abstract Objectives
This retrospective, observational, non‐interventional study describes the demographics, characteristics, immunological and virological status, coinfections, healthcare unit of HIV diagnosis and follow‐up status of Ukrainian refugees with newly diagnosed HIV in the Czech Republic, with a special focus on those with a late HIV ...Zofia Bartovská, Ricardo Massmann, David Jilich, Tomáš Groh, Lukáš Fleischhans, Milan Zlámal, Radek Svačinka, David Vydrář, Dalibor Sedláček, Miroslav Kubiska, Jaroslav Kapla, Lucie Nepovímová, Daniela Bartková, Lenka Olbrechtová, Zdeňka Jerhotová, Eva Novotná, Jakub Wnuk, Vratislav Němeček, Pavel Dlouhý, Štěpán Cimrman, Marek Malý +20 morewiley +1 more sourceSafety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort
HIV Medicine, Volume 26, Issue 6, Page 970-977, June 2025.Abstract Objectives
Most treatment switches are for simplification from three‐drug (3DR) to dual regimens (2DR). However, a proportion of people with HIV may switch back to 3DR, like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 2DR.Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi‐Lepri, Andrea Giacomelli, Roberto Rossotti, Giacomo Ponta, Nicoletta Bobbio, Alice Ianniello, Antonella Cingolani, Giordano Madeddu, Andrea Antinori, Antonella d'Arminio Monforte, on behalf of ICONA Foundation Study Group, A. d'Arminio Monforte, A. Antinori, S. Antinori, A. Castagna, R. Cauda, G. Di Perri, E. Girardi, R. Iardino, A. Lazzarin, G. C. Marchetti, C. Mussini, E. Quiros‐Roldan, L. Sarmati, B. Suligoi, F. Von Schloesser, P. Viale, A. d'Arminio Monforte, A. Antinori, A. Castagna, F. Ceccherini‐Silberstein, A. Cingolani, A. Cozzi‐Lepri, A. Di Biagio, E. Girardi, A. Gori, S. Lo Caputo, G. Marchetti, F. Maggiolo, C. Mussini, M. Puoti, C. F. Perno, C. Torti, A. Antinori, A. Bandera, S. Bonora, A. Calcagno, D. Canetti, A. Castagna, F. Ceccherini‐Silberstein, A. Cervo, A. Cingolani, P. Cinque, A. Cozzi‐Lepri, A. d'Arminio Monforte, A. Di Biagio, R. Gagliardini, A. Giacomelli, E. Girardi, N. Gianotti, A. Gori, G. Guaraldi, S. Lanini, G. Lapadula, M. Lichtner, A. Lai, S. Lo Caputo, G. Madeddu, F. Maggiolo, V. Malagnino, G. Marchetti, A. Mondi, V. Mazzotta, C. Mussini, S. Nozza, C. F. Perno, S. Piconi, C. Pinnetti, M. Puoti, E. Quiros Roldan, R. Rossotti, S. Rusconi, M. M. Santoro, A. Saracino, L. Sarmati, V. Spagnuolo, N. Squillace, V. Svicher, L. Taramasso, C. Torti, A. Vergori, A. Cozzi‐Lepri, S. De Benedittis, I. Fanti, M. Giotta, C. Marelli, A. Rodano, A. Tavelli, M. Cernuschi, L. Cosmaro, A. Perziano, V. Calvino, D. Russo, M. Farinella, N. Policek, V. L. Del Negro, M. Augello, S. Carrara, S. Graziano, G. Prota, S. Truffa, D. Vincenti, R. Rovito, M. Sgarlata, I. A Giacometti, A. Costantini, V. Barocci, A. Saracino, C. Santoro, E. Milano, L. Comi, C. Suardi, P. Viale, L. Badia, S. Cretella, E. M. Erne, A. Pieri, E. Quiros Roldan, E. Focà, B. Menzaghi, C. Abeli, L. Chessa, F. Pes, P. Maggi, L. Alessio, G. Nunnari, B. M. Celesia, J. Vecchiet, K. Falasca, A. Pan, S. Dal Zoppo, D. Segala, F. Bartalesi, C. Costa, S. Lo Caputo, S. Ferrara, M. Bassetti, E. Pontali, S. Blanchi, N. Bobbio, C. Del Borgo, R. Marocco, G. Mancarella, S. Piconi, C. Molteni, S. Rusconi, G. Canavesi, G. Pellicanò, G. Marchetti, S. Antinori, G. Rizzardini, M. Puoti, A. Castagna, A. Bandera, V. Bono, M. V. Cossu, A. Giacomelli, R. Lolatto, M. C. Moioli, L. Pezzati, S. Diotallevi, C. Tincati, C. Mussini, M. Menozzi, P. Bonfanti, G. Lapadula, V. Sangiovanni, I. Gentile, V. Esposito, N. Coppola, F. M. Fusco, G. Di Filippo, V. Rizzo, N. Sangiovanni, S. Martini, A. M. Cattelan, D. Leoni, A. Cascio, M. Trizzino, D. Francisci, E. Schiaroli, G. Parruti, F. Sozio, D. Messeri, S. I. Bonelli, C. Lazzaretti, R. Corsini, A. Antinori, R. Cauda, C. Mastroianni, L. Sarmati, A. Latini, A. Cingolani, I. Mastrorosa, S. Lamonica, M. Capozzi, M. Camici, I. Mezzaroma, M. Rivano Capparuccia, G. Iaiani, C. Stingone, L. Gianserra, J. Paulicelli, M. M. Plazzi, G. d'Ettore, M. Fusto, M. Lichtner, I. Coledan, G. Madeddu, A. De Vito, M. Fabbiani, F. Montagnani, A. Franco, R. Fontana Del Vecchio, D. Francisci, C. Di Giuli, G. C. Orofino, G. Calleri, G. Di Perri, S. Bonora, G. Accardo, C. Tascini, A. Londero, G. Battagin, S. Nicolè, G. Starnini, S. Dell'Isola +238 morewiley +1 more sourceNatural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models
Liver International, Volume 45, Issue 6, June 2025.ABSTRACT
Background and Aims: Drug‐induced liver injury (DILI) remains a leading cause of acute liver failure worldwide. Drugs such as isoniazid, alone or in combination with other anti‐tuberculosis drugs, as well as a growing number of herbal and complementary medicines, have been implicated in most cases of acute liver failure in registry studies ...Harshad C. Devarbhavi, Raúl J. Andradewiley +1 more source
